Laura S Wood

Author PubWeight™ 8.78^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.	Cancer	2014	2.05
2	Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.	J Clin Oncol	2008	2.00
3	Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).	Oncologist	2009	1.08
4	Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.	Onco Targets Ther	2009	1.07
5	Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.	Target Oncol	2014	0.96
6	Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.	BJU Int	2010	0.92
7	Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.	Cancer	2011	0.86
8	Introduction. Management of GU malignancies.	Semin Oncol Nurs	2012	0.75